Welcome to our dedicated page for Springworks Therapeutics news (Ticker: SWTX), a resource for investors and traders seeking the latest updates and insights on Springworks Therapeutics stock.
SpringWorks Therapeutics reports developments in rare-disease and oncology medicines as a healthcare company of Merck KGaA, Darmstadt, Germany. Its news centers on OGSIVEO® (nirogacestat), an oral gamma secretase inhibitor for adults with progressing desmoid tumors who require systemic treatment, and EZMEKLY® (mirdametinib) for symptomatic, inoperable NF1-associated plexiform neurofibromas.
Recurring updates include clinical data publications from the Phase 3 DeFi trial, U.S. and European regulatory actions, orphan-drug designations, product commercialization, and targeted-therapy pipeline work in solid tumors and hematological cancers. Corporate news also reflects SpringWorks' completed acquisition by Merck KGaA and related public-company status changes.
SpringWorks Therapeutics, Inc. (SWTX) will participate in the BofA Securities 2024 Health Care Conference in Las Vegas. Management will engage in a fireside chat on May 14, 2024, at 3:40 p.m. PT / 6:40 p.m. ET. Investors can access the live webcast on the company's website.
SpringWorks Therapeutics reported first quarter 2024 financial results and highlighted recent business updates with $21.0 million in OGSIVEO net product revenue, FDA approval of a Supplemental NDA for OGSIVEO, validation from EMA for MAA of nirogacestat, initiation of rolling submission of NDA for mirdametinib, and Phase 2b ReNeu trial results acceptance at ASCO Annual Meeting.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.